research reports and media, page-1503

I read it as no comprehensive evidence exists for DMOAD at the moment. The trials just haven't been done...

Having watched Dr Joughin's latest proactive interview, I could feel a real sense of excitement for the results of the 008.

I invested in PAR early 2019 based off a vet saying "it got rid of my arthritis" and my dad saying "give it to me now. My thumbs are killing me" (unfortunately developed oa in both thumbs during his first year of retirement).

Having researched further (including reading as much @Mozzarc titles as he can write), and understanding where PAR now sit, I better grasp why the differentiation between pain reducing treatment and disease modifying is so important.

I'm quietly confident 008 will be positive and have increased my position in the lead up to 'IND go live' as I see that as an inflection point at which the sp will rerate and steadily climb on the back of consistent positive news.